What Claradol Caféine treats: main uses and benefits

This formulation is used in situations involving certain distressing symptoms, particularly applied in clinical settings that involve acute or unstable symptom patterns associated with mild to moderate pain. It is considered relevant for easing symptoms that become more disruptive during flare-ups. The medication is commonly used to help address symptom clusters that may become intense or disruptive, such as various types of headaches, dental pain, period pains, and pain from muscular aches and rheumatic discomfort.

This combination supports the patient during difficult episodes by easing distress associated with temporary physiological imbalance. It is also applied across domains where additional symptomatic support is needed for systemic imbalance and symptoms related to flu-like conditions, including high temperature. The overall therapeutic role is focused on symptomatic management:

“...supports the patient during symptomatic periods by easing the overall symptom burden.”

It is relevant when symptoms become more noticeable, and may assist with maintaining functional stability when symptoms interfere with routine activities.

---

Quick Fact: Symptomatic Support for Acute and Systemic Discomfort Claradol Caféine is commonly used to help manage the dual presentation of pain and fever, and provides supportive relief when symptoms become temporarily overwhelming.

Who Can and Cannot Use Claradol Caféine?

The population eligibility for Claradol Caféine is strictly defined by regulatory documents, focusing on age, reproductive status, and pre-existing health conditions.

Contraindicated Populations (Must Not Use)

Classification	Population/Condition
Absolute Contraindication	Individuals with known hypersensitivity to paracetamol, caffeine, or any excipients.
Severe Organ Dysfunction	Patients with severe hepatic impairment or active liver disease.
Pediatric Exclusion	Children under 12 years of age are contraindicated/not recommended for use.

---

Populations with Use Restrictions

Adults and adolescents aged 16 years and over are generally eligible for use. However, use is restricted or requires medical advice for other specific groups:

• Age and Development: Adolescents aged 12 to 15 years are eligible but subject to lower maximum daily dose restrictions.
• Organ Function: Patients with renal impairment or mild to moderate hepatic impairment require caution and potential dose adjustment.
• Physiological States: Use is not recommended during pregnancy and lactation due to the caffeine content.
• Comorbidities: Caution is advised for patients with hypertension, heart disease, hyperthyroidism, or those in glutathione depleted states (e.g., chronic alcoholism or malnutrition).

Interactions with other medicines and products

---

Interaction Classifications and Restrictions

The regulatory profile for this combination is defined by constraints on co-administration with other medicines and substances. Co-use with other Paracetamol- or Acetaminophen-containing products is formally prohibited by regulatory authorities to eliminate the risk of severe hepatic injury. The profile includes substances that modify the medicine's metabolic handling.

Exposure-Modifying and Pharmacodynamic Interactions

• Hepatic enzyme-inducing drugs (e.g., Carbamazepine, Rifampicin, St John's Wort) may increase the potential for hepatic damage by altering Paracetamol metabolism.
• Prokinetic agents such as Metoclopramide may increase the speed of Paracetamol absorption. Conversely, Colestyramine may reduce absorption; however, this reduction is minimal if the sequestrant is administered one hour after Paracetamol.
• Prolonged regular use of Paracetamol with Warfarin may enhance the anticoagulant effect, increasing the risk of bleeding. Occasional doses are noted to have no significant effect.
• Caffeine may increase the clearance of Lithium.

Substance-Use Cautions

Specific restrictions apply to non-medicinal substances. Excessive intake of dietary caffeine (e.g., coffee, energy drinks) must be avoided due to the documented potential for increased caffeine-related adverse effects. The profile also notes that regular, excessive alcohol consumption may increase the risk of Paracetamol-related hepatotoxicity. Specific caution is documented for patients in Glutathione-Depleted States (e.g., chronic malnutrition) regarding an increased risk of metabolic acidosis.

Claradol Caféine combines two active pharmacological agents: Paracetamol (Acetaminophen) and Caffeine. Paracetamol primarily exerts its action within the central nervous system (CNS) by modulating cyclooxygenase (COX) activity, notably through the inhibition of prostaglandin (PG) synthesis. This effect reduces the level of prostaglandin E2 in the CNS, a mediator involved in certain physiological signaling cascades.

Caffeine, a methylxanthine, acts as a nonselective antagonist at all adenosine receptor subtypes (A1, A2A, A2B, A3), which are G-protein coupled receptors. This antagonism blocks the inhibitory effects of endogenous adenosine. Furthermore, caffeine facilitates a pharmacodynamic potentiation of paracetamol’s activity, possibly involving accelerated gastrointestinal absorption of paracetamol, or through a synergistic inhibition of prostaglandin synthesis within microglial cells by modulating COX-2 protein synthesis. The combined action results in a modified systemic biochemical environment and central nervous signaling.

Claradol Caféine is a fixed-dose combination product containing 500 mg of Acetaminophen and 65 mg of Caffeine per tablet. The official route of administration is oral, with the tablet intended to be swallowed whole with water. Standard protocols emphasize that the product must be taken strictly as required for symptoms and must not be used simultaneously with any other medicine containing acetaminophen.

The usage schedule is time-restricted, mandating a minimum interval between doses and defining maximum daily limits.

Population	Single Dose	Minimum Interval	Max Daily Dose
Adults (age ge 16)	Two tablets	4 hours	Eight tablets
Adolescents (12 -15 years)	One tablet	4 hours	Four tablets

The duration of continuous use is limited; the medicine is intended for short-term, symptomatic application. Established usage limits specify a maximum of 5 days for pain and 3 days for fever.

Official usage protocols include considerations for specific populations. Patients with hepatic or renal impairment are required to use a reduced dose or extend the interval between doses. Furthermore, while using this product, it is recommended within standard protocols to limit the concurrent intake of dietary caffeine (such as coffee, tea, or cola). These rules collectively establish the boundaries for the proper administration of the medicine.

Research Evidence / Overview of Studies for Claradol Caféine

This overview describes the research landscape for the combination of acetaminophen (paracetamol) and caffeine, focusing on the types of clinical studies that have been conducted, the symptom changes that were measured, and the limitations and uncertainties that remain in the evidence base. This information helps contextualize the research that has been observed so far.

---

Evidence for Use in Acute Pain and Adjuvant Effect

The combination of acetaminophen and caffeine was observed in numerous controlled studies. The core evidence for this use comes from systematic reviews and meta-analyses that pool data from numerous short-term Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms in adult participants experiencing various conditions associated with acute or disruptive episodes.

Researchers examined how the fixed-dose combination performed when compared directly to the single analgesic ingredient (acetaminophen) alone and to an inactive placebo. The primary outcomes measured in these trials were related to physical discomfort, specifically tracking the proportion of participants reaching a defined threshold on pain scales over a designated observation period. Research so far describes patterns where the study's measured outcomes for the combination differed from those observed for the single ingredient alone.

---

Evidence for Use in Primary Headaches

The evidence base is consistently derived from controlled clinical trials focusing on conditions characterized by fluctuating or episodic manifestations, particularly in individuals with episodic tension-type headaches and acute migraine attacks.

Studies explored not only changes in pain intensity but also other outcomes reflecting daily functioning or activity level. For instance, researchers monitored the proportion of participants who reported absence of pain at two hours post-dose, and assessed how symptoms associated with headaches evolved in the observed populations. Trials describe patterns related to the proportion of participants reporting absence of pain when compared against placebo.

---

Duration of Effect and Follow-up in Studies

The design of the current evidence base means that studies have primarily focused on research exploring short-term symptom changes. The observation periods for the key efficacy trials were limited, typically ranging from four to six hours after a single administration. Because the focus is on research exploring short-term symptom changes, long-term effects are not fully established. The results of existing studies reflect the specific, acute conditions under which they were conducted.

---

Gaps in Research and Areas of Uncertainty

The evidence highlights where more investigation is needed:

• Long-term Use: The follow-up durations were limited, meaning the long-term effects are not fully established.
• Subgroup Data: Few data are available from dedicated, large-scale controlled trials that specifically studied the combination in pediatric populations or in the older adult population.
• Causal Relationship: The available evidence helps establish group patterns, not personal predictions. Research provides context but does not determine whether an individual will respond similarly.

Key Studies & References

1. Caffeine as an analgesic adjuvant for acute pain in adults: a systematic review and meta-analysis
2. Summary of Product Characteristics - Paracetamol / Caffeine 500mg/65mg Tablets (HPRA)

Common questions about Claradol Caféine (FAQ)

---

Q: Is Claradol Caféine available without a prescription?

A: The regulatory scheduling and supply conditions for this medicine generally classify it as a pharmacy-only or over-the-counter (OTC) product. This generally means it is available as a pharmacy-only or over-the-counter product. Specific national regulations and labeling requirements for the medicine may vary depending on the country.

Q: How quickly does Claradol Caféine usually start to work?

A: Studies and official information indicate that the inclusion of caffeine accelerates the absorption of the paracetamol component. The combined effect suggests a faster onset of action compared to taking paracetamol on its own. Paracetamol’s highest concentration in the blood typically occurs between 30 minutes and 2 hours after ingestion.

Q: What is the typical duration of effects for Claradol Caféine?

A: The official regulatory guidelines require a minimum of 4 hours between doses for adults, which provides an indication of the medicine’s intended duration of effect. Furthermore, the half-life of the caffeine component in an average adult is reported to be around 5 hours. Consulting the product label for the specified minimum dosing interval is necessary.

Q: What is the difference between Claradol Caféine and a regular pain reliever?

A: Claradol Caféine is a fixed-dose combination that contains two active ingredients: paracetamol (an analgesic) and caffeine (an adjuvant). Research evidence suggests that this combination provides an enhanced level of pain relief when compared directly to taking the single paracetamol ingredient on its own.

Q: Does Claradol Caféine cause drowsiness or make people tired?

A: The active components are classified as Central Nervous System (CNS) stimulants, meaning they are associated with effects such as nervousness and insomnia. The medicine is generally not associated with causing drowsiness, as it avoids the sedative side effects linked to some other classes of pain relievers.

Q: Can Claradol Caféine be used for muscle aches or joint pain?

A: Official indications focus on the medicine's use for acute pain, and this includes generalized aches and pains. The medicine is used for the symptomatic relief of general acute pain, which covers common musculoskeletal discomfort.

Q: Is Claradol Caféine safe for people over 65 years old?

A: Official product labeling notes that clinical trial data specifically focused on the older adult population are limited. For this reason, general caution is advised, and a potential dose adjustment may be necessary based on professional guidance.

Q: What happens if Claradol Caféine is taken close to bedtime?

A: Due to its caffeine component, official advice suggests limiting use late in the day or in the evening. This is a common precaution intended to help prevent the occurrence of insomnia or difficulty sleeping.

Q: Are there any specific supplements that interact with Claradol Caféine?

A: The herbal supplement St John's Wort is specifically mentioned in regulatory documents as a substance that may interact with the medicine. It is classified as a hepatic enzyme-inducing drug, and the interaction could increase the potential for hepatic damage associated with paracetamol.

Q: Do food or dairy products affect how Claradol Caféine works?

A: Official administration instructions recommend swallowing the tablet whole with a large glass of liquid, such as water. There is no specific instruction indicating that food or dairy products affect the core function of the medicine.

Q: Is it possible to develop a tolerance to Claradol Caféine?

A: Tolerance, which is the need for increasing amounts to achieve the same effect, has been described in literature related to the caffeine component. This is a recognized pattern associated with methylxanthine compounds.

Q: Is Claradol Caféine meant to be taken with food or on an empty stomach?

A: Official administration instructions require swallowing the tablet whole with water. Official regulatory instructions do not specify taking the medicine with or without food.

Q: Are there any known effects on alertness or driving ability?

A: Official regulatory texts typically do not include a specific driving contraindication for this medicine. However, the medicine is associated with adverse effects like nervousness or headache, which may impact alertness and concentration.

Q: Is the caffeine content in Claradol Caféine comparable to a cup of coffee?

A: Each Claradol Caféine tablet contains 65 mg of caffeine. For comparison, the caffeine content in an average cup of brewed coffee typically ranges from approximately 95 mg to 200 mg.

Q: Can I take Claradol Caféine if I am sensitive to aspirin?

A: The medicine is classified as an Analgesic and Antipyretic combination. The official classification distinguishes the medicine from the NSAID class (Non-steroidal Anti-inflammatory Drugs), to which aspirin belongs.

Q: Are there any known issues with taking Claradol Caféine before surgery?

A: In general, it is advisable to seek guidance regarding all medicines prior to any surgical procedure. The product profile specifically notes that prolonged regular use of paracetamol alongside warfarin may enhance anticoagulant effects, which is a relevant consideration in a surgical context.

Q: Does Claradol Caféine have any effects on stomach lining?

A: The medicine is classified as a non-NSAID, distinguishing it from drugs commonly linked to irritation of the stomach lining. However, it is noted that acute pancreatitis (inflammation of the pancreas) has been reported as a serious adverse event in cases of overdose.

Q: What are the general rules for stopping Claradol Caféine if I feel better?

A: Official guidelines describe the medicine as intended for short-term, symptomatic use only. This instruction implies that use should cease when the symptoms of pain or fever have improved. The medicine should be taken strictly as required to manage symptoms.

Q: What is the general safety profile of Claradol Caféine?

A: When used strictly within the recommended dosage and package size limits, the combination of paracetamol and caffeine is described in regulatory contexts as having an 'excellent risk:benefit profile.' Patients must follow all maximum dosage and duration limits precisely, as exceeding them carries significant risk.

Q: What type of pain is Claradol Caféine most effective against?

A: Research evidence and official indications focus on its use in acute conditions, particularly headaches. This includes episodic tension-type headaches, acute migraine attacks, and other forms of general acute pain. It is used when enhanced pain relief is sought.

Q: Can Claradol Caféine be used by people with a history of anxiety?

A: The caffeine component is a known Central Nervous System (CNS) stimulant, and common side effects include nervousness and insomnia. The use of this medicine requires caution for patients with pre-existing conditions like hypertension or heart disease, suggesting caution is needed where stimulant effects are relevant.

Q: Does Claradol Caféine have a potential for misuse or dependency?

A: Official safety materials document the potential for Analgesic Overuse Headache with frequent, prolonged use. The caffeine component is also associated in regulatory literature with the possibility of developing physical dependence and withdrawal symptoms.

Q: Is it possible to get withdrawal symptoms when stopping Claradol Caféine?

A: Regulatory-validated symptoms related to caffeine withdrawal include headache, fatigue, decreased energy or activeness, and difficulty concentrating. Symptoms of caffeine withdrawal are known to occur after abstinence.

How to Store and Dispose of Claradol Caféine?

The official storage and disposal requirements for Claradol Caféine are documented to ensure product stability and environmental safety.

Storage Requirement	Official Regulatory Instruction
Temperature / Light	Store below 25 C and keep in the original container to protect from light.
Container Integrity	The medication must be kept in the container it came in, tightly closed.
Child Safety	Mandatory instruction: Keep the product out of the sight and reach of children.
Stability Limit	Do not use the medicine after the expiry date (EXP) printed on the packaging.

Disposal Instructions

Regulatory agencies state that Claradol Caféine must not be disposed of via wastewater or household trash. Unused or expired medication should be returned to a pharmacist or local collection point as a measure to help protect the environment. These protocols are required by official product labeling to maintain the quality of the medication and ensure appropriate waste management.